MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Kura Oncology Inc

Cerrado

SectorSanidad

10.05 6.46

Resumen

Variación precio

24h

Actual

Mínimo

9.42

Máximo

10.38

Métricas clave

By Trading Economics

Ingresos

-8.7M

-66M

Ventas

1.2M

15M

Margen de beneficios

-432.509

Empleados

192

EBITDA

-8M

-73M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+175.72% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

238M

786M

Apertura anterior

3.59

Cierre anterior

10.05

Noticias sobre sentimiento de mercado

By Acuity

40%

60%

161 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Kura Oncology Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

7 oct 2025, 16:58 UTC

Ganancias

BMW Trims 2025 View, Citing Weaker Performance in China

7 oct 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 oct 2025, 23:36 UTC

Charlas de Mercado

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 oct 2025, 23:19 UTC

Charlas de Mercado

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 oct 2025, 22:50 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 oct 2025, 22:50 UTC

Charlas de Mercado

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 oct 2025, 22:40 UTC

Charlas de Mercado

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 oct 2025, 21:56 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

7 oct 2025, 21:56 UTC

Charlas de Mercado

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

7 oct 2025, 20:44 UTC

Acciones populares

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 oct 2025, 19:42 UTC

Charlas de Mercado

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 oct 2025, 19:23 UTC

Adquisiciones, fusiones, absorciones

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 oct 2025, 19:07 UTC

Charlas de Mercado

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 oct 2025, 19:02 UTC

Charlas de Mercado

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 oct 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

7 oct 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

7 oct 2025, 16:20 UTC

Charlas de Mercado

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 oct 2025, 16:15 UTC

Charlas de Mercado

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 oct 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

7 oct 2025, 15:37 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 oct 2025, 15:37 UTC

Charlas de Mercado

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 oct 2025, 15:33 UTC

Charlas de Mercado

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 oct 2025, 15:25 UTC

Charlas de Mercado

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 oct 2025, 15:15 UTC

Charlas de Mercado

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 oct 2025, 15:04 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

7 oct 2025, 15:04 UTC

Charlas de Mercado

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 oct 2025, 14:56 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 oct 2025, 14:56 UTC

Charlas de Mercado

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 oct 2025, 14:52 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Comparación entre iguales

Cambio de precio

Kura Oncology Inc previsión

Precio Objetivo

By TipRanks

175.72% repunte

Estimación a 12 Meses

Media 26 USD  175.72%

Máximo 40 USD

Mínimo 11 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kura Oncology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

11

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

5.575 / 6.6Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

161 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.
help-icon Live chat